

PRESS RELEASE – FOR IMMEDIATE RELEASE

2019 revenue: €8.3 million, up +20%, and cash position of €2.8 million at December 31

- Strong increase in sequencing services, driven by activities related to the SeqOIA sequencing platform and by activities with the Institut Pasteur
- Sales growth for Mercury®, Sirius® and Galileo® sequencing data interpretation software
- Generation of positive operational cash flow in the second half enabling a cash balance of €2.8 million compared with €2.6 million at June 30, 2019

EVRY, FRANCE, FRIDAY 10 JANUARY 2020, 08H00 - IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), a company specializing in the decryption of the human genome, which performs interpretable genomic analyzes for academic and private laboratories, announced today its unaudited business figures for the year 2019.

2019 revenue amounted to 8.3 M € versus 6.9 M € in 2018, an increase of 20% over 12 months. This performance highlights an acceleration from the high growth level of 15% reported for the first half of 2019.

The growth in sales is linked to the partnership with the Groupement Coopératif de Santé (GCS) SeqOIA, in which IntegraGen operates the sequencing platform, as well as the good performance of all business lines, in particular the sequencing platform in microbiology operated for the Institut Pasteur.

Sales of software and consulting services continued to grow, reaching €0.6 million over the whole year.

Cash balance at the end of 2019 was € 2.8m, up €200k compared to June 30, thanks to positive operating cash flows in the second half.

2020 OUTLOOK: CONTINUED SUSTAINED DYNAMIC GROWTH

Commercial momentum will continue in 2020 given the multi-year contracts in place and the increase in order intake for sequencing services activity. Revenues in the genomic data interpretation tools segment should also increase significantly in 2020.

Bernard Courtieu, Chairman and CEO of IntegraGen, stated “The 20% increase in our revenues in 2019, which reflects the good momentum of all of our offers (sequencing services, platform operations services for most prestigious institutions and interpretation software), and our efforts to optimize the

economic model, enabling us to generate a positive cash flow during the second half of the year . We reiterate our confidence in the prospects for profitable growth for 2020.”

The financial results for 2019 will be published on April 3, 2020 (before the financial markets open).

About IntegraGen

IntegraGen is a company specializing in the analysis of the human genome and performs adapted and quickly interpretable analyzes for academic and private laboratories. For the management of cancers, which are characterized by a genetic disruption of cells, IntegraGen provides researchers and doctors with universal and individualized therapeutic guidance tools allowing them to adapt the treatment to the patient's genetic profile.

IntegraGen has forty-six employees and generated revenue of €8.3 million in 2019. Based in the G n pole d'Evry, IntegraGen is also located in the United States in Cambridge, MA. IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 - Mnemo: ALINT - Eligible PEA-PME).

For more information, visit : www.integragen.com



CONTACTS

INTEGRAGEN

Bernard COURTIEU
President and CEO

Laurence RIOT LAMOTTE
Chief Financial Officer
contact@integragen.com
Tel: +33 (0)1 60 91 09 00

NEWCAP

Investor Relations

Emmanuel HUYNH
Louis-Victor DELOUVRIER
integragen@newcap.eu
Tel: +33 (0)1 44 71 98 53